Study Finds Early TNF Inhibitor Treatment Is Associated with Higher Heart Disease Risk in Ankylosing Spondylitis Patients — with Caveats

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found that early initiation of tumor necrosis factor (TNF) inhibitors was associated with higher risk of heart disease in patients diagnosed with ankylosing spondylitis.